Searching in Pharma & Drug Safety · Search everything
2,977 changes Pharma & Drug Safety
Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2
The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.
NURIX BTK Degrading Compounds, 36 Claims, Apr 14
The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.
ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant
The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.
Isoxazolo[5,4-H]quinazoline CDK Inhibitor Patent
USPTO granted patent US12600731B2 to Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. for isoxazolo[5,4-H]quinazoline compounds effective as cyclin-dependent kinase (CDK) inhibitors for treating cell proliferation disorders. The patent contains 23 claims and covers pharmaceutical compositions and methods of treating CDK-mediated diseases.
Halozyme US12600959B2 - Modified PH20 Hyaluronidase Polypeptides
USPTO granted Patent US12600959B2 to Halozyme, Inc. covering modified PH20 hyaluronidase polypeptides with enhanced stability and activity. The patent includes 15 claims spanning formulations, compositions, and uses thereof. Filing date was March 5, 2025, with application number 19071345.
Benzazepine derivative for vasopressin receptor disease treatment
Benzazepine derivative for vasopressin receptor disease treatment
Organoid Culture Compositions and Methods from Cryogenically Preserved Tissue
USPTO granted patent US12600953B2 to The Regents of the University of Michigan on April 14, 2026. The patent covers compositions and methods for establishing organoid cultures from cryogenically preserved tissue (e.g., human biopsy tissue), along with related methods of use. The application (No. 16634818) was filed on July 27, 2018, with eight claims allowed.
Modified Immune Cells with Adenosine Deaminase Base Editors for Gene Editing
USPTO granted Patent US12600971B2 to Beam Therapeutics Inc. covering genetically modified immune cells incorporating adenosine base editors (ABE8) for modifying nucleobases in target sequences. The patent contains 22 claims and was filed on February 13, 2020, under Application No. 17430676.
Translate Bio mRNA Synthesis Patent (US12600998B2)
USPTO granted patent US12600998B2 to Translate Bio, Inc. on April 14, 2026. The patent covers methods for large-scale production of full-length messenger RNA (mRNA) substantially free of double-stranded RNA using in vitro transcription with SP6 RNA polymerase. The patent contains 19 claims and was filed as application 17502816.